详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review.

12| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Medical Oncology, Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangzhou, Guangdong, P. R. China [2]Cancer Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P. R. China [3]Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY [4]Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

出处：

DOI：

ISSN：

关键词： Compound mutations Epithelial growth factor receptor Nonesmall-cell lung cancer Osimertinib Uncommon mutations

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2019]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.3 最新[2023版] 3.4 最新五年平均 3.55 出版当年[2019版] 3.565 出版当年五年平均 4.117 出版前一年[2018版] 4.785 出版后一年[2020版]

第一作者：

第一作者机构： [1]Department of Medical Oncology, Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangzhou, Guangdong, P. R. China

共同第一作者：

通讯作者：

通讯机构： [4]Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY [*1]Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid [2]非小细胞肺癌少见/罕见靶点:共识与争鸣 [3]Curcumin inhibits cell proliferation and migration in NSCLC through a synergistic effect on the TLR4/MyD88 and EGFR pathways. [4]Novel compound heterozygous mutations in TELO2 in an infant with You-Hoover-Fong syndrome: A case report and literature review [5]Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report [6]Circulating tumor DNA analysis for osimertinib resistance Chinese NSCLC patients [7]Circulating tumor DNA analysis for osimertinib resistance Chinese NSCLC patients. [8]SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification [9]Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/in trans-C797S Mutations After Resistance to Osimertinib [10]Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells